Methylphenidate

also known as MPH · Ritalin · Concerta · Methylphenidate Hydrochloride · OROS Methylphenidate · methylphenidate HCL · OROS-MPH · DAYTRANA · +63 more

Small molecule targets ABCB1

Developed for: attention deficit-hyperactivity disorder · Alzheimer disease · cocaine dependence · substance-related disorder · traumatic brain injury · cancer · post-traumatic stress disorder · autism spectrum disorder
+67 more
· cognitive disorder · depressive disorder · myalgic encephalomeyelitis/chronic fatigue syndrome · major depressive disorder · methamphetamine dependence · obesity disorder · Parkinson disease · alcohol-related disorders · attention deficit hyperactivity disorder, inattentive type · bipolar disorder · brain injury · cognitive impairment with or without cerebellar ataxia · diabetes mellitus · disruptive behavior disorder · epilepsy · hematopoietic and lymphoid cell neoplasm · mood disorder · prostate cancer · sleep disorder · stroke disorder · 22q11.2 deletion syndrome · acute lymphoblastic leukemia · alcohol dependence · anxiety · autonomic nervous system disorder · binge eating disorder · borderline personality disorder · brain hypoxia - ischemia · brain neoplasm · cancer-related condition · central nervous system neoplasm · cerebral palsy · childhood apraxia of speech · chronic progressive multiple sclerosis · conduct disorder · delirium · developmental coordination disorder · fetal alcohol spectrum disorder · fragile X syndrome · head and neck cancer · insomnia · ischemic stroke · multiple sclerosis · neurofibromatosis type 1 · orthostatic hypotension · persian gulf syndrome · poisoning · prostate carcinoma · relapsing-remitting multiple sclerosis · schizoaffective disorder · sickle cell disease · substance abuse · trichotillomania · velocardiofacial syndrome · Williams syndrome · AIDS dementia complex · chronic pain syndrome · Down syndrome · intellectual disability · KBG syndrome · manic bipolar affective disorder · movement disorder · myotonic dystrophy type 1 · obsessive-compulsive disorder · oppositional defiant disorder · pervasive developmental disorder · vascular dementia
Investigated by: Massachusetts General Hospital · National Institute of Mental Health (NIMH) · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · National Institute on Drug Abuse (NIDA) · M.D. Anderson Cancer Center · National Cancer Institute (NCI)
+259 more
· Ortho-McNeil Janssen Scientific Affairs, LLC · Rhodes Pharmaceuticals, L.P. · Purdue Pharma, Canada · Shalvata Mental Health Center · Children's Hospital Medical Center, Cincinnati · Hospital de Clinicas de Porto Alegre · Icahn School of Medicine at Mount Sinai · Johns Hopkins University · New York State Psychiatric Institute · Pfizer · Alza Corporation · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Duke University · Federal University of Rio Grande do Sul · National Institute of Neurological Disorders and Stroke (NINDS) · National Institutes of Health (NIH) · Novartis · Purdue Pharma LP · VA Office of Research and Development · Cincinnati MDRU · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Florida International University · Ironshore Pharmaceuticals and Development, Inc · Janssen-Ortho Inc., Canada · Noven Therapeutics · Oregon Health and Science University · Seattle Children's Hospital · Sheba Medical Center · Shire · Sunnybrook Health Sciences Centre · US Department of Veterans Affairs · University Hospital, Basel, Switzerland · University of Florida · University of Utah · Yale University · Allameh Tabatabai University · Bispebjerg Hospital · Boston Children's Hospital · Brock University · Eli Lilly and Company · Hallym University Medical Center · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Janssen Korea, Ltd., Korea · Janssen-Cilag International NV · Johnson & Johnson Taiwan Ltd · K-PAX Pharmaceuticals, Inc. · Maastricht University Medical Center · Medical University of South Carolina · Memorial Sloan Kettering Cancer Center · Mental Health Centre Sct. Hans (Denmark) · NYU Langone Health · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Taiwan University Hospital · Ostfold Hospital Trust · Portland VA Medical Center · Region Västmanland · Shaare Zedek Medical Center · Soroka University Medical Center · The Leiden Academic Center for Drug Research (LACDR) · The Ministry of Science, Technology and Innovation, Denmark · The University of Texas Health Science Center, Houston · Tong Lee · Tri-Service General Hospital (TSGH) · University of California, Los Angeles · University of Copenhagen · University of Geneva, Switzerland · University of Michigan · University of Nebraska · University of South Florida · University of Zurich · ANRS, Emerging Infectious Diseases · Aalborg University Hospital · Aarhus University Hospital Skejby · Akili Interactive Labs, Inc. · all 265 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Tuzulby	—	2025-02-28	europa.eu ↗
Label expansion	US (FDA)	ADHANSIA XR	—	2021-06-28	fda.gov ↗
Label expansion	US (FDA)	APTENSIO XR	—	2019-06-14	fda.gov ↗
Label expansion	US (FDA)	DAYTRANA	—	2010-06-29	fda.gov ↗
Label expansions (3)	US (FDA)	CONCERTA	—	2004-10-21 – 2009-11-04	fda.gov ↗
Approved	US (FDA)	RITALIN	—	1955-12-05	fda.gov ↗

Trials 301 · started per year

today

US approved 1955

EU approved 2025

1954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 010 trials
Phase 0	NCT06063200	Mar 2024 → Jul 2025	alcohol-related disorders, attention deficit-hyperactivity disorder	University of Florida	Completed	No outcome recorded
Phase 0	NCT05978167	Jun 2023 → Mar 2031 expected	substance-related disorder	Icahn School of Medicine at Mount Sinai	Active not recruiting	No outcome recorded
Phase 0	NCT05675098	May 2023 → Feb 2025 overdue	cerebral palsy, neurodevelopmental disorder	Kuwait University	Not yet recruiting	No outcome recorded
Phase 0	NCT04501653	Jun 2021 → Mar 2023	—	Washington University School of Medicine	Completed	No outcome recorded
Phase 0	NCT04737512	Feb 2021 → Oct 2024	attention deficit-hyperactivity disorder	Yale University	Completed	No outcome recorded
Phase 0	NCT03190681	Jul → Nov 2017	impulse control disorder	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 0	NCT02874690	Feb 2016 → Aug 2017	attention deficit-hyperactivity disorder, autism spectrum disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 0	NCT02021214	Mar → Oct 2014	post-traumatic stress disorder	University of California, San Diego	Completed	No outcome recorded
Phase 0	NCT01951508	Oct 2013 → Dec 2014	mood disorder, substance-related disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 0	NCT01616407	Aug → Dec 2012	CGF1	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 124 trials · 1 missed
Phase 1	NCT06977308	Oct 2026 → Oct 2029 expected	early-onset schizophrenia	New York State Psychiatric Institute	Not yet recruiting	No outcome recorded
Phase 1	NCT07314333	Feb → Mar 2026	attention deficit-hyperactivity disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT03814356	Aug 2020 → Apr 2024 overdue	brain hypoxia - ischemia, traumatic brain injury	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 1	NCT03652740	Oct 2018 → Feb 2024	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT04273880	Apr 2018 → Dec 2024	—	University of British Columbia	Unknown	No outcome recorded
Phase 1	NCT03769064	Mar → Jun 2018	substance abuse	Avekshan LLC	Completed	No outcome recorded
Phase 1	NCT02700711	Feb 2016 → Jun 2018	substance-related disorder	University of Kentucky	Completed	No outcome recorded
Phase 1	NCT02327195	May 2014 → Jan 2018	—	Nicoleta Stoicea	Completed	No outcome recorded
Phase 1	NCT01924468	Aug 2013 → Sep 2018	nicotine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 1	NCT01978431	Nov 2012 → May 2014	cocaine dependence, impulse control disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT01465685	Dec 2011 → Dec 2012	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01164956	Jul 2011 → Mar 2013	cancer	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 1	NCT01834547	May 2011 → Apr 2013	—	K. Lieb	Completed	No outcome recorded
Phase 1	NCT02453698	Jan 2011 → Jan 2012	—	The Hospital for Sick Children	Completed	No outcome recorded
Phase 1	NCT01290276	Dec 2010 → Aug 2012	—	Tong Lee	Completed	No outcome recorded
Phase 1	NCT01202734	Sep → Oct 2010	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT01045083	Jan 2010 → Jun 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00603434	Jan 2008 → Mar 2009	amphetamine abuse, methamphetamine dependence	University of Cincinnati	Completed	No outcome recorded
Phase 1	NCT01040702	Jan 2008 → Aug 2009	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Completed	No outcome recorded
Phase 1	NCT00220493	Jun 2003 → Jun 2005	chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis	Sheba Medical Center	Unknown	No outcome recorded
Phase 1	NCT02361125	Aug 2002 → Dec 2021	—	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00223691	Mar 2002 → Jan 2017	autonomic nervous system disorder, orthostatic hypotension	Vanderbilt University	Completed	Mixed
Phase 1	NCT00136734	Apr 1998 → Mar 2004	attention deficit-hyperactivity disorder, cocaine dependence	New York State Psychiatric Institute	Completed	Missed primary
Phase 1	NCT00015067	Dec 1997 → ?	substance-related disorder	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 1/28 trials · 1 missed
Phase 1/2	NCT04885257	Jan 2022 → May 2025	post-traumatic stress disorder, stroke disorder	VA Office of Research and Development	Completed	Missed primary
Phase 1/2	NCT03610282	Nov 2019 → Nov 2020	—	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT02429076	Jun 2017 → Jul 2019	—	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 1/2	NCT02696512	Mar 2016 → Mar 2017	brain injury	International Brain Research Foundation	Unknown	No outcome recorded
Phase 1/2	NCT02051452	Nov 2014 → May 2018	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 1/2	NCT02247986	Sep 2014 → May 2015	attention deficit-hyperactivity disorder, conduct disorder	National Institute of Mental Health (NIMH)	Withdrawn	No outcome recorded
Phase 1/2	NCT01907360	Aug → Oct 2013	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Completed	No outcome recorded
Phase 1/2	NCT00772161	Oct → Dec 2008	attention deficit-hyperactivity disorder	University Hospital Freiburg	Completed	No outcome recorded
Phase 235 trials · 1 met primary · 1 missed
Phase 2	NCT07306078	May 2026 → Apr 2028 expected	alcohol-related disorders	University of Florida	Not yet recruiting	No outcome recorded
Phase 2	NCT07279740	Jan 2026 → Oct 2027 expected	Alzheimer disease	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
Phase 2	NCT05669924	Sep 2022 → Apr 2024	—	Northwestern University	Completed	No outcome recorded
Phase 2	NCT05414058	Sep 2022 → Aug 2024	schizoaffective disorder	The Royal Ottawa Mental Health Centre	Completed	No outcome recorded
Phase 2	NCT05133804	Jun 2022 → Jul 2025 overdue	post-traumatic stress disorder	University of Haifa	Recruiting	No outcome recorded
Phase 2	NCT05185583	Mar 2022 → Oct 2025	childhood apraxia of speech	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 2	NCT03280251	Sep 2018 → Mar 2020	—	University Hospital, Lille	Completed	No outcome recorded
Phase 2	NCT03090269	Jun → Dec 2018	substance-related disorder	ANRS, Emerging Infectious Diseases	Withdrawn	No outcome recorded
Phase 2	NCT02970500	Oct 2017 → Dec 2022	cancer-related condition, female breast carcinoma	CHU de Quebec-Universite Laval	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02630017	Mar 2016 → Sep 2018	attention deficit-hyperactivity disorder	University of Arkansas	Completed	No outcome recorded
Phase 2	NCT02357030	Jan 2015 → May 2016	persian gulf syndrome	K-PAX Pharmaceuticals, Inc.	Unknown	No outcome recorded
Phase 2	NCT02286557	Oct 2014 → Feb 2025	myalgic encephalomeyelitis/chronic fatigue syndrome	Kessler Foundation	Completed	No outcome recorded
Phase 2	NCT02148783	Sep 2014 → Aug 2018	traumatic brain injury	Uniformed Services University of the Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02225106	Aug 2014 → Jun 2017	attention deficit-hyperactivity disorder, cognitive disorder, traumatic brain injury	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT01628029	Jan 2014 → Dec 2025 overdue	cancer, hematopoietic and lymphoid cell neoplasm, sleep disorder	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT02227056	Jan 2014 → Jan 2017	brain injury	Loewenstein Hospital	Completed	No outcome recorded
Phase 2	NCT01966276	Nov 2013 → Dec 2014	myalgic encephalomeyelitis/chronic fatigue syndrome	K-PAX Pharmaceuticals, Inc.	Unknown	No outcome recorded
Phase 2	NCT01921582	Aug 2013 → Sep 2015	binge eating disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 2	NCT01914822	Jul 2013 → Sep 2014	—	Rambam Health Care Campus	Completed	No outcome recorded
Phase 2	NCT01410942	Feb 2012 → Sep 2028 expected	prostate cancer	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT01377662	Aug 2011 → May 2013	cocaine dependence, methamphetamine dependence	Tong Lee	Completed	No outcome recorded
Phase 2	NCT01416948	Aug 2011 → Mar 2013	post-traumatic stress disorder, traumatic brain injury	INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01267292	Mar 2011 → Dec 2015	cocaine dependence	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 2	NCT01044238	Oct 2010 → Jul 2014	methamphetamine dependence	University of California, Los Angeles	Unknown	No outcome recorded
Phase 2	NCT01348607	Jul 2010 → Nov 2012	central nervous system cancer, sleep disorder	University of South Florida	Terminated	No outcome recorded
Phase 2	NCT01117181	Jun 2010 → Aug 2012	Alzheimer disease	Johns Hopkins Bloomberg School of Public Health	Completed	No outcome recorded
Phase 2	NCT01100268	Apr 2010 → Apr 2011	—	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT02695355	Oct 2006 → Jan 2013	attention deficit-hyperactivity disorder	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 2	NCT00364702	Aug 2006 → Jul 2007	attention deficit-hyperactivity disorder	Shaare Zedek Medical Center	Completed	No outcome recorded
Phase 2	NCT00359723	Jul 2004 → Jan 2006	Parkinson disease	Oregon Health and Science University	Completed	Missed primary
Phase 2	NCT00550147	Feb 2004 → Nov 2005	attention deficit-hyperactivity disorder	Indiana University	Completed	Met primary
Phase 2	NCT00069927	Aug 2003 → Jun 2006	childhood malignant neoplasm, depressive disorder, poisoning	University of South Florida	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00138138	Oct 2002 → Aug 2006	prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00015054	Sep 1998 → Oct 1999	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00015223	Jun 1997 → Jul 1999	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 2/36 trials · 1 missed
Phase 2/3	NCT05474846	Nov 2022 → Feb 2027 expected	anxiety, cancer, depressive disorder	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2/3	NCT05243186	Oct 2021 → Jul 2022	attention deficit-hyperactivity disorder	Ariel University	Unknown	No outcome recorded
Phase 2/3	NCT03772834	Mar 2019 → Nov 2026 expected	prostate carcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2/3	NCT01896700	Jul 2013 → Apr 2016	multiple sclerosis	Oregon Health and Science University	Completed	No outcome recorded
Phase 2/3	NCT00424099	Jan 2007 → Nov 2021	cancer of unknown primary site	M.D. Anderson Cancer Center	Completed	Missed primary
Phase 2/3	NCT02215538	Nov 2004 → Feb 2006	attention deficit-hyperactivity disorder	University of Utah	Completed	No outcome recorded
Phase 359 trials · 18 met primary · 6 missed
Phase 3	NCT06905587	Sep 2025 → Dec 2029 expected	brain cancer, myalgic encephalomeyelitis/chronic fatigue syndrome	Odense University Hospital	Recruiting	No outcome recorded
Phase 3	NCT06431256	Sep 2024 → Jul 2025	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Terminated	No outcome recorded
Phase 3	NCT05832489	Feb 2024 → May 2027 expected	attention deficit-hyperactivity disorder	University Hospital, Strasbourg, France	Recruiting	No outcome recorded
Phase 3	NCT05842330	Jan 2024 → Oct 2026 expected	attention deficit-hyperactivity disorder	Stéphanie Baggio	Recruiting	No outcome recorded
Phase 3	NCT05880342	May 2023 → Dec 2025 overdue	—	Vrije Universiteit Brussel	Recruiting	No outcome recorded
Phase 3	NCT03481959	May 2019 → Sep 2020	attention deficit-hyperactivity disorder	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT03618030	Aug 2018 → Jul 2019	attention deficit-hyperactivity disorder	Purdue Pharma, Canada	Completed	Met primary
Phase 3	NCT03525873	Aug 2018 → Dec 2026 expected	metastatic malignant neoplasm	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 3	NCT03218254	Jun 2018 → Oct 2021	hematopoietic and lymphoid cell neoplasm	Henrik Frederiksen	Unknown	No outcome recorded
Phase 3	NCT03185065	Oct 2017 → Nov 2019	myalgic encephalomeyelitis/chronic fatigue syndrome	Johns Hopkins University	Completed	Missed primary
Phase 3	NCT03172481	May → Aug 2017	attention deficit-hyperactivity disorder	Purdue Pharma, Canada	Completed	Met primary
Phase 3	NCT02754258	Jan 2017 → Aug 2018	obesity disorder	Children's Hospital of Eastern Ontario	Unknown	No outcome recorded
Phase 3	NCT02704390	Jan 2016 → Aug 2019	attention deficit-hyperactivity disorder	Orient Pharma Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02493777	Jul 2015 → Feb 2016	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Completed	Met primary
Phase 3	NCT02168127	May 2014 → May 2015	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT02139124	Apr → Oct 2014	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	Met primary
Phase 3	NCT01654250	Jul → Oct 2012	attention deficit-hyperactivity disorder	Pfizer	Completed	Met primary
Phase 3	NCT01773837	Jan 2012 → Feb 2018	—	Clinica Universidad de Navarra, Universidad de Navarra	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01675804	Nov 2011 → Apr 2012	attention deficit-hyperactivity disorder	Allameh Tabatabai University	Completed	No outcome recorded
Phase 3	NCT01351272	May 2011 → Dec 2012	attention deficit-hyperactivity disorder	Wuerzburg University Hospital	Completed	Missed primary
Phase 3	NCT01338818	Apr 2011 → Feb 2013	attention deficit-hyperactivity disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01497548	Mar 2011 → Sep 2012	major depressive disorder	University of Malaya	Unknown	Met primary
Phase 3	NCT01269463	Jan → Jun 2011	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	Met primary
Phase 3	NCT01109849	Nov 2010 → Apr 2016	attention deficit-hyperactivity disorder	Florida International University	Completed	No outcome recorded
Phase 3	NCT01239030	Nov 2010 → Feb 2012	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	Met primary
Phase 3	NCT00904670	Apr → Aug 2009	attention deficit-hyperactivity disorder	Pfizer	Completed	Met primary
Phase 3	NCT00599287	Feb → May 2008	delirium	UMC Utrecht	Terminated	No outcome recorded
Phase 3	NCT00376675	Feb 2008 → Jun 2010	cancer of unknown primary site	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 3	NCT00714688	Feb 2008 → Apr 2009	attention deficit-hyperactivity disorder	Janssen-Cilag International NV	Completed	Met primary
Phase 3	NCT00541346	Sep 2007 → May 2009	attention deficit-hyperactivity disorder, autism spectrum disorder	University of Oklahoma	Completed	No outcome recorded
Phase 3	NCT00501293	Aug 2007 → Feb 2009	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00506285	Jun 2007 → Apr 2009	attention deficit-hyperactivity disorder	University of Utah	Completed	Met primary
Phase 3	NCT00482313	May 2007 → Apr 2010	attention deficit-hyperactivity disorder	Psychiatry Karolinska	Completed	Met primary
Phase 3	NCT00428792	Apr → Dec 2007	attention deficit-hyperactivity disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00273741	Jan 2007 → Jun 2009	neoplasm	University Hospital, Grenoble	Terminated	No outcome recorded
Phase 3	NCT01411280	Jun 2006 → May 2009	sickle cell disease	Temple University	Completed	No outcome recorded
Phase 3	NCT00326300	Apr 2006 → Aug 2007	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 3	NCT00326391	Apr → Dec 2006	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	Met primary
Phase 3	NCT00307684	Jan 2006 → Jul 2008	attention deficit-hyperactivity disorder	Janssen-Cilag International NV	Completed	Missed primary
Phase 3	NCT00254878	Oct 2005 → Feb 2006	attention deficit-hyperactivity disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00246233	Jun 2005 → Apr 2006	major depressive disorder	Janssen-Ortho Inc., Canada	Completed	Missed primary
Phase 3	NCT00246220	Mar 2005 → Nov 2006	attention deficit-hyperactivity disorder	Janssen Pharmaceutica N.V., Belgium	Completed	Met primary
Phase 3	NCT00246207	Mar → Dec 2005	attention deficit-hyperactivity disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00301639	Mar → Dec 2005	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00151957	Oct 2004 → Jun 2007	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00516269	Aug 2004 → Dec 2013	breast cancer, digestive system cancer	M.D. Anderson Cancer Center	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT00485550	Jan 2004 → Mar 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00486083	Dec 2003 → Oct 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT05041946	Jul 2003 → Dec 2004	cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00031798	Apr 2002 → Mar 2005	central nervous system neoplasm, cognitive disorder, depressive disorder	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00249353	Mar → Oct 2002	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	Met primary
Phase 3	NCT00018863	Apr 2001 → Mar 2006	attention deficit-hyperactivity disorder	New York State Psychiatric Institute	Completed	Met primary
Phase 3	NCT00003266	Oct 1999 → May 2002	cancer of unknown primary site	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 3	NCT00269776	Nov 1998 → Jan 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00269789	Mar → May 1998	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00693212	Feb 1986 → Nov 1994	attention deficit-hyperactivity disorder	University of Utah	Completed	No outcome recorded
Phase 3	NCT00269802	? → Feb 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	Met primary
Phase 3	NCT00304681	? → Feb 2004	attention deficit-hyperactivity disorder	Janssen-Ortho Inc., Canada	Completed	Met primary
Phase 3	NCT00269815	? → Dec 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded

Phase 4110 trials · 9 met primary · 1 missed
Phase 4	NCT07710014	Oct 2026 → Jul 2027 expected	attention deficit-hyperactivity disorder	Dar Clinical Research Inc.	Recruiting	No outcome recorded
Phase 4	NCT07650643	Sep 2026 → May 2031 expected	attention deficit-hyperactivity disorder	Boston Children's Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07594652	May 2026 → Dec 2030 expected	attention deficit-hyperactivity disorder	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Recruiting	No outcome recorded
Phase 4	NCT07121621	Sep 2025 → Sep 2026 overdue	attention deficit-hyperactivity disorder, obesity disorder	University Hospital, Tours	Not yet recruiting	No outcome recorded
Phase 4	NCT06577779	Jan 2025 → Jun 2026 overdue	attention deficit-hyperactivity disorder	NYU Langone Health	Recruiting	No outcome recorded
Phase 4	NCT06580041	Nov 2024 → Sep 2029 expected	major depressive disorder	University of California, San Francisco	Enrolling by invitation	No outcome recorded
Phase 4	NCT06077669	Apr 2024 → Dec 2028	attention deficit-hyperactivity disorder	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 4	NCT05776056	Feb 2024 → Jul 2026 overdue	post-traumatic stress disorder	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT04419272	Aug 2023 → May 2028 expected	epilepsy	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT05469386	Jun 2022 → Aug 2025 overdue	attention deficit-hyperactivity disorder	Florida International University	Active not recruiting	No outcome recorded
Phase 4	NCT04968522	Feb 2022 → Apr 2023	fetal alcohol spectrum disorder	Monash Medical Centre	Unknown	No outcome recorded
Phase 4	NCT04987762	Aug 2021 → Apr 2022	attention deficit-hyperactivity disorder	Purdue Pharma LP	Terminated	No outcome recorded
Phase 4	NCT04781972	Jul 2021 → Nov 2028 expected	attention deficit-hyperactivity disorder	Johns Hopkins University	Recruiting	No outcome recorded
Phase 4	NCT04741516	Dec 2020 → Dec 2023	attention deficit-hyperactivity disorder	JPM van Stralen Medicine Professional	Unknown	No outcome recorded
Phase 4	NCT04421248	Sep 2020 → Feb 2026 overdue	attention deficit-hyperactivity disorder	Donald Gilbert, MD, MS, FAAN, FAAP	Recruiting	No outcome recorded
Phase 4	NCT04507204	Jul 2020 → Dec 2021	attention deficit-hyperactivity disorder	Purdue Pharma LP	Terminated	No outcome recorded
Phase 4	NCT04283877	Dec 2019 → Dec 2021	—	Brock University	Unknown	No outcome recorded
Phase 4	NCT03811847	Nov 2019 → Aug 2021	Alzheimer disease	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT04152629	Sep 2019 → Jul 2021	attention deficit-hyperactivity disorder	Purdue Pharma, Canada	Completed	No outcome recorded
Phase 4	NCT03785223	Apr 2019 → Sep 2022	agoraphobia, attention deficit-hyperactivity disorder, generalized anxiety disorder, panic disorder +1	McMaster University	Completed	No outcome recorded
Phase 4	NCT03420339	Oct 2018 → Mar 2027 expected	attention deficit-hyperactivity disorder	Matthew J O'Brien, PhD, BCBA-D	Recruiting	No outcome recorded
Phase 4	NCT03546400	Sep 2018 → Dec 2020	attention deficit-hyperactivity disorder	Pfizer	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03536390	Sep 2018 → Apr 2021	attention deficit-hyperactivity disorder	Pfizer	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03511976	May 2018 → Oct 2023	attention deficit-hyperactivity disorder	Florida International University	Withdrawn	No outcome recorded
Phase 4	NCT04272021	Apr 2018 → Dec 2023	attention deficit-hyperactivity disorder	IRCCS Eugenio Medea	Unknown	No outcome recorded
Phase 4	NCT03781752	Mar 2018 → Aug 2025 overdue	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 4	NCT05974241	Apr 2017 → Apr 2022	attention deficit-hyperactivity disorder, mood disorder	Tri-Service General Hospital (TSGH)	Completed	No outcome recorded
Phase 4	NCT04349917	Dec 2016 → Mar 2020	attention deficit-hyperactivity disorder	University of North Carolina, Chapel Hill	Completed	Mixed
Phase 4	NCT02677519	Sep 2016 → Apr 2017	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Unknown	No outcome recorded
Phase 4	NCT02477280	Sep 2016 → Jun 2021	attention deficit-hyperactivity disorder, substance-related disorder	Region Västmanland	Completed	No outcome recorded
Phase 4	NCT02470234	Jul 2016 → Jul 2017	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 4	NCT02807870	Jun 2016 → Dec 2019	attention deficit-hyperactivity disorder	University of Sao Paulo	Completed	Mixed
Phase 4	NCT02683265	Apr 2016 → Nov 2017	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 4	NCT02473185	Sep 2015 → Jun 2018	attention deficit-hyperactivity disorder	Region Västmanland	Completed	No outcome recorded
Phase 4	NCT01858064	Apr 2015	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 4	NCT02326038	Nov 2014 → Dec 2015	cognitive impairment with or without cerebellar ataxia	Maastricht University Medical Center	Unknown	No outcome recorded
Phase 4	NCT02255565	Sep 2014 → Sep 2016	attention deficit-hyperactivity disorder, autism spectrum disorder	Seattle Children's Hospital	Completed	No outcome recorded
Phase 4	NCT02178995	Aug 2014 → Sep 2015	cognitive disorder, epilepsy	Kimford Jay Meador	Completed	Mixed
Phase 4	NCT02153944	Jun 2014 → Oct 2021	anxiety disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT02096952	May 2014 → Jan 2018	attention deficit-hyperactivity disorder, autism spectrum disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT03250013	Apr 2014 → Jan 2022	attention deficit-hyperactivity disorder	Göteborg University	Completed	No outcome recorded
Phase 4	NCT02147535	Mar → Aug 2014	butyrylesterase 1	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT01933217	Nov 2013 → Aug 2016	attention deficit-hyperactivity disorder, traumatic brain injury	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 4	NCT01993108	Oct 2013 → Dec 2015	attention deficit-hyperactivity disorder	University of Michigan	Completed	Missed primary
Phase 4	NCT01831622	Jun 2013 → Jun 2015	attention deficit-hyperactivity disorder	Mats Fredriksen	Completed	No outcome recorded
Phase 4	NCT01764672	Apr 2013 → Apr 2015	attention deficit-hyperactivity disorder	Iris Sommer	Withdrawn	No outcome recorded
Phase 4	NCT02501798	Jan 2013 → Jul 2015	attention deficit-hyperactivity disorder	VU University of Amsterdam	Completed	No outcome recorded
Phase 4	NCT01825577	Nov 2012 → Feb 2015	dementia	St. Louis University	Terminated	No outcome recorded
Phase 4	NCT01678209	Oct 2012 → Apr 2018	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT01673594	Sep 2012 → Jun 2015	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT02074228	Aug 2012 → Jul 2015	attention deficit-hyperactivity disorder	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT02623114	May 2012 → Aug 2016	attention deficit-hyperactivity disorder	Seoul National University Childrens Hospital	Unknown	No outcome recorded
Phase 4	NCT02135263	Apr 2012 → May 2014	butyrylesterase 1	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT01244269	Dec 2010 → Jun 2011	Parkinson disease	Laval University	Terminated	No outcome recorded
Phase 4	NCT01228604	Dec 2010 → Dec 2013	attention deficit-hyperactivity disorder	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 4	NCT01133847	Nov 2010 → Jun 2015	attention deficit-hyperactivity disorder, reading disorder	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT02566824	Oct 2010 → Aug 2020	attention deficit-hyperactivity disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
Phase 4	NCT00931398	Apr 2010	attention deficit-hyperactivity disorder	University of Pittsburgh	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT01933880	Dec 2009 → Nov 2010	attention deficit-hyperactivity disorder	Xian-Janssen Pharmaceutical Ltd.	Completed	Met primary
Phase 4	NCT01063153	Sep 2009 → Feb 2012	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00937040	Jul 2009 → Feb 2010	attention deficit-hyperactivity disorder	Ortho-McNeil Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 4	NCT00799487	Jan → Jun 2009	attention deficit-hyperactivity disorder	Ortho-McNeil Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 4	NCT00815841	Jan → Dec 2009	—	Shaare Zedek Medical Center	Unknown	No outcome recorded
Phase 4	NCT00799409	Dec 2008 → Jun 2009	attention deficit-hyperactivity disorder	Ortho-McNeil Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 4	NCT00792662	Nov 2008 → Dec 2011	Alzheimer disease, diabetes mellitus	University of Nebraska	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00794625	Nov 2008 → Nov 2012	attention deficit-hyperactivity disorder	Joseph Blader	Unknown	Met primary
Phase 4	NCT00778310	Nov 2008 → Dec 2010	attention deficit-hyperactivity disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 4	NCT00754208	Sep 2008 → Jan 2010	attention deficit-hyperactivity disorder	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT00862108	Sep 2008 → Mar 2010	attention deficit-hyperactivity disorder	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT01012622	Sep 2008 → Aug 2009	attention deficit-hyperactivity disorder	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00796302	Aug 2008 → Nov 2012	attention deficit-hyperactivity disorder	Michael Aman	Completed	Met primary
Phase 4	NCT01060150	Jul 2008 → Apr 2010	attention deficit-hyperactivity disorder	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT01065259	Apr 2008 → Dec 2010	attention deficit-hyperactivity disorder	Peking University	Completed	No outcome recorded
Phase 4	NCT00758160	Mar → Jun 2008	attention deficit-hyperactivity disorder	Johnson & Johnson Taiwan Ltd	Completed	No outcome recorded
Phase 4	NCT01000402	Feb 2008 → Oct 2012	attention deficit-hyperactivity disorder, bipolar disorder	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
Phase 4	NCT00552266	Oct 2007 → Oct 2009	attention deficit-hyperactivity disorder, trichotillomania	Geha Mental Health Center	Unknown	No outcome recorded
Phase 4	NCT00536419	Sep 2007 → Sep 2008	attention deficit-hyperactivity disorder	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
Phase 4	NCT00495820	Aug 2007 → Mar 2010	Alzheimer disease	VA Office of Research and Development	Completed	Met primary
Phase 4	NCT00429273	Jan 2007 → Jul 2011	attention deficit-hyperactivity disorder	University of California, Los Angeles	Completed	Met primary
Phase 4	NCT00434213	Jan → Aug 2007	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 4	NCT00593112	Nov 2006 → May 2009	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00396058	Nov 2006 → Mar 2008	stroke disorder	University of Aarhus	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00518232	Sep 2006 → Jun 2007	attention deficit-hyperactivity disorder	Johnson & Johnson Taiwan Ltd	Completed	No outcome recorded
Phase 4	NCT01727414	Jun 2006 → Jul 2013	attention deficit hyperactivity disorder, inattentive type	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 4	NCT00842127	Mar 2006 → Aug 2008	attention deficit-hyperactivity disorder	Bundang CHA Hospital	Completed	No outcome recorded
Phase 4	NCT00773916	Mar 2006 → Jul 2008	attention deficit-hyperactivity disorder	Federal University of Rio Grande do Sul	Completed	No outcome recorded
Phase 4	NCT01220440	Jan 2006 → Dec 2008	attention deficit-hyperactivity disorder	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 4	NCT00302458	Jan 2006 → Jun 2007	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00261872	Dec 2005 → Apr 2007	alcohol dependence, attention deficit-hyperactivity disorder	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 4	NCT00757029	Oct 2005 → Aug 2008	attention deficit-hyperactivity disorder	Hallym University Medical Center	Completed	No outcome recorded
Phase 4	NCT00257725	Mar 2005 → Mar 2008	attention deficit-hyperactivity disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00318981	Dec 2004 → Dec 2006	attention deficit-hyperactivity disorder	University of Maryland, College Park	Completed	Met primary
Phase 4	NCT00302354	Dec 2004 → Sep 2005	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00169611	Jan 2004 → Jan 2011	neurofibromatosis type 1	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 4	NCT00302367	Jan → Apr 2004	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00585910	Jan 2004 → Dec 2007	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00181714	Nov 2003 → Jan 2011	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00254033	Oct 2003 → Oct 2006	Alzheimer disease	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT00302406	Jul 2003 → Nov 2007	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00223561	Feb 2003 → Feb 2006	attention deficit-hyperactivity disorder	Utrecht Institute for Pharmaceutical Sciences	Completed	No outcome recorded
Phase 4	NCT00181987	Aug 2002 → Aug 2005	attention deficit-hyperactivity disorder, bipolar disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00381758	May → Aug 2002	attention deficit-hyperactivity disorder	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT02951754	Feb 2002 → Dec 2032 expected	attention deficit-hyperactivity disorder	Hospital de Clinicas de Porto Alegre	Recruiting	No outcome recorded
Phase 4	NCT00517504	May 2001 → Mar 2008	attention deficit-hyperactivity disorder	University of Arizona	Completed	No outcome recorded
Phase 4	NCT00768820	May 2001 → Aug 2027 expected	Williams syndrome, fragile X syndrome, velocardiofacial syndrome	The Chaim Sheba Medical Center	Recruiting	No outcome recorded
Phase 4	NCT00576472	Jan 2000 → Mar 2010	acute lymphoblastic leukemia, brain neoplasm	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 4	NCT00663442	Dec 1999 → Nov 2004	attention deficit-hyperactivity disorder	University of Illinois at Chicago	Completed	No outcome recorded
Phase 4	NCT00000388	Sep 1998 → Nov 1999	attention deficit-hyperactivity disorder, disruptive behavior disorder, substance-related disorder	NYU Langone Health	Completed	No outcome recorded
Phase 4	NCT00035139	—	traumatic brain injury	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 4	NCT00866996	? → Dec 2003	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded

Phase not applicable49 trials · 1 met primary · 2 missed
—	NCT05761756	Nov 2023 → Jan 2027	—	Duke University	Suspended	No outcome recorded Stop: Business
—	NCT06369714	Feb 2023 → Dec 2025 overdue	attention deficit-hyperactivity disorder, neurodevelopmental disorder	Lei Lei, MD	Recruiting	No outcome recorded
—	NCT05561205	Feb 2023 → Dec 2026 expected	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
—	NCT05410626	Jun → Aug 2022	attention deficit-hyperactivity disorder	Mahidol University	Unknown	No outcome recorded
—	NCT04964427	Feb 2021 → Oct 2022	attention deficit-hyperactivity disorder	Bambino Gesù Hospital and Research Institute	Completed	No outcome recorded
—	NCT04384562	Dec 2020 → Dec 2021	—	University of Zurich	Completed	No outcome recorded
—	NCT03936491	Aug 2019 → Jan 2021	attention deficit-hyperactivity disorder	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT04371146	Jul 2019 → Feb 2020	—	University of Zurich	Completed	No outcome recorded
—	NCT04065906	Jan → Dec 2019	attention deficit-hyperactivity disorder	Xijing Hospital	Unknown	No outcome recorded
—	NCT03595826	May 2018 → May 2019	attention deficit-hyperactivity disorder, developmental coordination disorder	University of KwaZulu	Completed	No outcome recorded
—	NCT03515668	Apr 2018 → Dec 2021	—	Brock University	Unknown	No outcome recorded
—	NCT02643732	Nov 2016 → May 2018	sarcoidosis	University of East Anglia	Unknown	No outcome recorded
—	NCT04647500	Aug 2016 → Sep 2022	22q11.2 deletion syndrome	University of Geneva, Switzerland	Completed	No outcome recorded
—	NCT02822937	Jul → Nov 2016	—	Akili Interactive Labs, Inc.	Completed	No outcome recorded
—	NCT02625805	Apr → Oct 2016	attention deficit-hyperactivity disorder	Brainmarc Ltd.	Completed	No outcome recorded
—	NCT02704546	Apr 2016 → Apr 2017	—	Sheba Medical Center	Unknown	No outcome recorded
—	NCT02180529	Nov 2015 → Jun 2020	cognitive disorder	Meir Medical Center	Terminated	No outcome recorded Stop: Enrollment
—	NCT02780102	Sep 2015 → Mar 2016	attention deficit-hyperactivity disorder	Allameh Tabatabai University	Completed	No outcome recorded
—	NCT03358277	Nov 2014 → Aug 2017	disruptive behavior disorder	Tri-Service General Hospital (TSGH)	Completed	No outcome recorded
—	NCT02162381	Jun 2014 → Apr 2018	—	Rabin Medical Center	Completed	Mixed
—	NCT02152670	May → Jun 2014	cocaine dependence	Yale University	Terminated	No outcome recorded
—	NCT03411434	Feb 2014 → Dec 2019	attention deficit-hyperactivity disorder	Centre Hospitalier Rouffach	Unknown	No outcome recorded
—	NCT03788902	Feb 2014 → Dec 2016	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Completed	No outcome recorded
—	NCT02020200	Jan → Dec 2014	BD syndrome	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT02071615	Aug 2013 → Mar 2014	—	Charite University, Berlin, Germany	Completed	No outcome recorded
—	NCT01683032	Oct 2012 → May 2013	—	Shalvata Mental Health Center	Completed	No outcome recorded
—	NCT01852344	Jun 2012 → Jun 2013	—	University of Michigan	Completed	Missed primary
—	NCT01426984	May 2012 → May 2013	borderline personality disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT01554046	Oct 2011 → Apr 2014	attention deficit hyperactivity disorder, inattentive type	Sheba Medical Center	Completed	No outcome recorded
—	NCT00817960	Jul 2011 → Jan 2012	—	Soroka University Medical Center	Completed	No outcome recorded
—	NCT01218425	Nov 2010 → Jun 2012	—	Maastricht University Medical Center	Completed	No outcome recorded
—	NCT01124032	May 2010 → Jan 2011	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT01124500	May 2010 → May 2012	head and neck cancer	Memorial Sloan Kettering Cancer Center	Withdrawn	No outcome recorded
—	NCT01912352	May 2010 → Apr 2013	attention deficit-hyperactivity disorder	Seoul National University	Completed	No outcome recorded
—	NCT00989950	Dec 2009 → Feb 2011	attention deficit-hyperactivity disorder, insomnia	Cox Health Systems	Completed	Missed primary
—	NCT00972985	Sep → Dec 2009	—	Orasi Medical, Inc.	Completed	No outcome recorded
—	NCT00844090	Jul 2009 → Aug 2012	diabetes mellitus	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00485797	Oct 2007 → Mar 2008	attention deficit-hyperactivity disorder	Soroka University Medical Center	Completed	No outcome recorded
—	NCT00548652	Aug 2007 → May 2009	obesity disorder	VA Nebraska Western Iowa Health Care System	Completed	No outcome recorded
—	NCT00572026	Jul 2007 → Jul 2009	attention deficit-hyperactivity disorder	University of Virginia	Unknown	No outcome recorded
—	NCT00715520	Apr 2007 → Sep 2016	ischemic stroke	Emory University	Completed	No outcome recorded
—	NCT00780208	Apr 2007 → Oct 2008	attention deficit-hyperactivity disorder	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00393562	Mar 2006 → Oct 2007	Parkinson disease	US Department of Veterans Affairs	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00580814	Feb 2006 → Mar 2009	attention deficit-hyperactivity disorder	University of California, Irvine	Completed	No outcome recorded
—	NCT00129467	Feb 2005 → Sep 2009	cancer, depressive disorder	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00824317	Oct 2001 → Feb 2005	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
—	NCT00025779	Oct 2001 → Nov 2003	attention deficit-hyperactivity disorder, autism	National Institute of Mental Health (NIMH)	Completed	Met primary
—	NCT00012584	Nov 2000 → May 2002	attention deficit-hyperactivity disorder, generalized anxiety disorder, separation anxiety disorder, social phobia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00441649	Feb 2000 → Jun 2004	Tourette syndrome, attention deficit-hyperactivity disorder	Stony Brook University	Completed	No outcome recorded

Comparator or background therapy120 trials
Phase 0	NCT06759298 Comparator	Jan → Mar 2025 overdue	borderline personality disorder	Tanta University	Not yet recruiting	No outcome recorded
Phase 0	NCT02233829 Comparator	Apr 2024	cocaine abuse	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Withdrawn	No outcome recorded Stop: Enrollment
Phase 0	NCT03519022 Comparator	Jun 2018 → May 2019	substance-related disorder	Craig Rush	Completed	No outcome recorded
Phase 0	NCT03190954 Comparator	Aug 2017 → Oct 2025	opiate dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 0	NCT02879136 Comparator	Jan 2017 → Dec 2025	Parkinson disease	Hubert Fernandez	Completed	No outcome recorded
Show all 120 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 13

Date	Issuer	Release
2024-11-19	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Mixed Salts of a Single-Entity Amphetamine Extended-Release Capsules lupin.com ↗
2023-10-26	Aytu BioPharma, Inc.	Regulatory Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement aytubio.com ↗ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS).
2023-07-10	Aytu BioPharma, Inc.	Regulatory Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement aytubio.com ↗ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, has submitted the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA).
2022-03-23	Aytu BioPharma, Inc.	Regulatory Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R) aytubio.com ↗ The listing of this patent extends the Orange Book patent exclusivity for Cotempla XR-ODT by over five years.
2019-07-19	Zydus Lifesciences Limited	Regulatory Zydus Nesher Pharmaceuticals receives final approval from the USFDA zyduslife.com ↗ Zydus’ Nesher Pharmaceuticals receives final approval from the USFDA for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate ER Capsules
2017-07-17	Impax Laboratories, LLC	Regulatory Impax Announces FDA Approval of its AB Rated Generic Concerta® (Methylphenidate Hydrochloride) Extended-Release Tablets CII amneal.com ↗
2016-11-30	Lannett Company, Inc.	Regulatory Lannett Provides Update On Methylphenidate ER Tablets investorroom.com ↗ Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) granted the company a 90-day extension to submit documentation concerning its Methylphenidate Hydrochloride (HCl) Extended-Release (ER) Tablets.
2016-10-19	Lannett Company, Inc.	Regulatory Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets investorroom.com ↗ Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's Abbreviated New Drug Application (ANDA) for Methylphenidate Hydrochloride (HCl) Extended-Release (ER) Tablets.
2016-02-17	Impax Laboratories, LLC	Regulatory Impax Receives FDA Approval for Generic Version of Adderall XR® (mixed salts of a single-entity amphetamine product) Capsules, CII amneal.com ↗ HAYWARD, Calif. , Feb. 17, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration ( FDA ) has approved its Abbreviated New Drug Application (ANDA) for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate (mixed salts of a single-entity amphetamine product) extended-release capsules, CII, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.
2015-12-07	Pfizer	Regulatory Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII pfizer.com ↗ Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets.
2014-07-17	Takeda	Results Top-Line Results From Two Head-To-Head Studies Comparing Vyvanse® (Lisdexamfetamine Dimesylate), CII, With Concerta® (Methylphenidate Hcl), CII, In Adolescents With ADHD takeda.com ↗ In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to Concerta on the primary efficacy analysis (p = 0.0013) with mean reductions on the ADHD RS-IV total score of 25.4 and 22.1 points, respectively.
2004-06-25	Eli Lilly and Company	Results Strattera Controlled Symptoms of ADHD with Minimal Effect on Sleep lilly.com ↗ Additionally, parent diaries showed children on Strattera were less irritable compared to methylphenidate.
2003-11-19	Impax Laboratories, LLC	Regulatory IMPAX ANDA Filing for Generic Version of Adderall XR Accepted by FDA amneal.com ↗ IMPAX Laboratories, Inc. (Nasdaq:IPXL) today announced that the United States Food and Drug Administration (FDA) has accepted the Company's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Adderall XR(R) 30mg Capsules.

All press releases naming this drug 38 releases

Date	Issuer	Release
2026-09-23	Sun Pharmaceutical Industries, Inc.	Sun Pharma Launches CTaro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System sunpharma.com ↗
2026-05-12	BioDelivery Sciences International	Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics collegiumpharma.com ↗
2026-03-19	BioDelivery Sciences International	Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory collegiumpharma.com ↗
2026-03-03	BioDelivery Sciences International	Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community collegiumpharma.com ↗
2025-03-06	Noven Therapeutics	Noven Provides Update on Daytrana® (methylphenidate transdermal system), CII Supply and Ongoing Efforts to Resolve Shortage noven.com ↗
2024-11-19	Lupin Limited	Lupin Receives Approval from U.S. FDA for Mixed Salts of a Single-Entity Amphetamine Extended-Release Capsules lupin.com ↗
2024-10-01	Aytu BioPharma, Inc.	Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada aytubio.com ↗
2023-10-26	Aytu BioPharma, Inc.	Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement aytubio.com ↗
2023-07-31	Aytu BioPharma, Inc.	Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority aytubio.com ↗
2023-07-10	Aytu BioPharma, Inc.	Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement aytubio.com ↗
2022-03-23	Aytu BioPharma, Inc.	Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R) aytubio.com ↗
2021-11-05	ZevraDenmark	KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD zevra.com ↗
2021-10-27	ZevraDenmark	AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress zevra.com ↗
2021-10-20	ZevraDenmark	KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October) zevra.com ↗
2021-07-21	ZevraDenmark	KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. zevra.com ↗
2021-04-21	ZevraDenmark	KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital zevra.com ↗
2021-04-08	ZevraDenmark	KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™ zevra.com ↗
2021-03-02	ZevraDenmark	KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD zevra.com ↗
2019-07-19	Zydus Lifesciences Limited	Zydus Nesher Pharmaceuticals receives final approval from the USFDA zyduslife.com ↗
2019-05-29	Lannett Company, Inc.	Lannett Commences Marketing Generic Concerta® investorroom.com ↗
2018-08-03	Lannett Company, Inc.	Lannett Enters Licensing Agreement for Generic Concerta®, Methylphenidate Hydrochloride ER Tablets investorroom.com ↗
2018-02-05	Impax Laboratories, LLC	Amneal Launches AB-Rated Generic for Concerta® amneal.com ↗
2017-07-17	Impax Laboratories, LLC	Impax Announces FDA Approval of its AB Rated Generic Concerta® (Methylphenidate Hydrochloride) Extended-Release Tablets CII amneal.com ↗
2017-07-05	Impax Laboratories, LLC	Impax Announces FDA Approval and Launch of Additional Strengths of Generic Focalin XR® (Dexmethylphenidate Hydrochloride) Extended-Release Capsules CII amneal.com ↗
2016-11-30	Lannett Company, Inc.	Lannett Provides Update On Methylphenidate ER Tablets investorroom.com ↗
2016-10-19	Lannett Company, Inc.	Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets investorroom.com ↗
2016-09-22	Impax Laboratories, LLC	Impax Launches Generic Version of Metadate CD® (Methylphenidate Hydrochloride Extended-Release Capsules) amneal.com ↗
2016-02-17	Impax Laboratories, LLC	Impax Receives FDA Approval for Generic Version of Adderall XR® (mixed salts of a single-entity amphetamine product) Capsules, CII amneal.com ↗
2015-12-07	Pfizer	Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII pfizer.com ↗
2014-07-17	Takeda	Top-Line Results From Two Head-To-Head Studies Comparing Vyvanse® (Lisdexamfetamine Dimesylate), CII, With Concerta® (Methylphenidate Hcl), CII, In Adolescents With ADHD takeda.com ↗
2012-09-14	Impax Laboratories, LLC	Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA® amneal.com ↗
2011-05-06	Impax Laboratories, LLC	Impax Laboratories Confirms Patent Suit Relating to Generic Concerta(R) 18, 27 and 36 mg Tablets amneal.com ↗
2010-11-29	Impax Laboratories, LLC	Impax Laboratories Confirms Patent Suit Relating to Generic Concerta(R) 54 mg Tablets amneal.com ↗
2010-10-01	Noven Therapeutics	Noven Completes Acquisition of Daytrana® Methylphenidate Transdermal System (Cii) From Shire noven.com ↗
2010-08-10	Noven Therapeutics	Noven To Acquire Daytrana® Methylphenidate Transdermal System From Shire noven.com ↗
2006-10-03	Impax Laboratories, LLC	IMPAX Announces Dismissal of Lawsuit Related to Generic Concerta(R) amneal.com ↗
2004-06-25	Eli Lilly and Company	Strattera Controlled Symptoms of ADHD with Minimal Effect on Sleep lilly.com ↗
2003-11-19	Impax Laboratories, LLC	IMPAX ANDA Filing for Generic Version of Adderall XR Accepted by FDA amneal.com ↗

Evidence & citations 76 cited values

Every value below carries the sentence it was read from. 472 sources stand behind the page.

Field	Value	Cited text
Known as	Methylphenidate	“Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 383 “Stimulant medications such as osmotic-release oral system methylphenidate (OROS-MPH) are first-line treatments in the general population, but they are under-prescribed in...” PMID 38178233 ↗ Jan 2024 “OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017 “A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy...” NCT02020200 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “OBJECTIVE: A preliminary study to examine the efficacy of osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) symptoms and...” PMID 19192455 ↗ Dec 2008 “Spheroidal Oral Drug Absorption System methylphenidate (SODAS-MPH) was administered twice daily, was titrated to ~1 mg/kg/d over 3 weeks, and was continued for 3 additional...” PMID 29617066 ↗ Mar 2018 “In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of...” NCT01962181 ↗ “Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and...” PMID 26779845 ↗ Jan 2016 “Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician.” NCT03511976 ↗ “NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.” PMID 23289899 ↗ Jan 2013 Show 373 more sources
Known as	298-59-9	“Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally” NCT05957055 ↗
Known as	Adhansia XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 2 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021
Known as	Aptensio	“Aptensio” NCT03420339 ↗
Known as	Aptensio XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 4 “The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children...” NCT02677519 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.” PMID 25877989 ↗ Apr 2015 NCT02683265 ↗
Known as	Azstarys	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Concerta	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 38 “The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult...” NCT00246233 ↗ “The purpose of this study is to determine the effectiveness and safety of OROS\methylphenidate/CONCERTA\ vs. immediate release methylphenidate as a treatment for ADHD...” NCT00304681 ↗ “The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for...” NCT00249353 ↗ “The Formal Observation of Concerta versUs Strattera (FOCUS) study was conducted to assess, in children with ADHD, treatment outcomes with Concerta [OROS methylphenidate (MPH)],...” PMID 16350601 ↗ Oct 2005 “OBJECTIVE: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the...” PMID 19440077 ↗ Jun 2009 “An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per...” NCT00326300 ↗ “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “This approach produced a new product (OROS-methylphenidate or Concerta), which proved to have the predicted rapid onset (with 1-2 hours) and long duration of efficacy (10-12...” PMID 12578439 ↗ Feb 2003 “CONCERTA (methylphenidate HCl) is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when...” NCT00799409 ↗ Show 28 more sources
Known as	Concerta-TM	“A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children...” NCT00485550 ↗
Known as	CONCERTAÒ	“OROS MPH (CONCERTAÒ 90mg)” NCT00302354 ↗
Known as	Cotempla XR-ODT	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	DAYTRANA	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 6 “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With...” NCT00434213 ↗ “Daytrana” NCT03420339 ↗ NCT00780208 ↗ NCT00989950 ↗
Known as	DR/ER-MPH	“Delayed-release/extended-release methylphenidate (DR/ER-MPH) (formerly HLD200) is an evening-dosed agent used for the treatment of attention-deficit/hyperactivity disorder.” PMID 37770309 ↗ Sep 2023
Known as	Extended Release Methylphenidate	“Extended Release Methylphenidate (OROS-Methylphenidate)” NCT00323947 ↗
Known as	Extended-Release Methylphenidate Hydrochloride	“A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children...” NCT00485550 ↗
Known as	Focalin	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Focalin XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Foquest	“The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®).” NCT04741516 ↗ 1 “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021
Known as	HLD200	“This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.” NCT01907360 ↗ 2 “The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core.” NCT02493777 ↗ “HLD200 methylphenidate hydrochloride capsules” NCT06431256 ↗
Known as	Immediate-release Methylphenidate	“This study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD)...” NCT00758160 ↗ 2 “A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults” NCT00302458 ↗ “a short immediate release-methylphenidate hydrochloride (IR-MPH)” NCT00302393 ↗
Known as	IR-MPH	“Stimulant treatment with immediate-release methylphenidate (IR MPH) has been demonstrated to improve driving performance in adolescents with ADHD.” NCT00572026 ↗ 1 “a short immediate release-methylphenidate hydrochloride (IR-MPH)” NCT00302393 ↗
Known as	Jornay PM	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 2 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “methylphenidate hydrochloride (Jornay PM)” NCT07594652 ↗
Known as	Metadate	“This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological...” NCT03519022 ↗ 1 “Metadate” NCT03420339 ↗
Known as	Metadate CD	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Methilphenidate	“Methilphenidate” NCT05551689 ↗
Known as	Methylin	“Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Methylin (liquid)	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	methylphenidate HCL	“The purpose of this study is to evaluate the effectiveness and safety of methylphenidate HCl extended-release tablets at five dose levels compared to placebo in adults with...” NCT00326391 ↗ 19 “The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity...” NCT00326300 ↗ “CONCERTA (methylphenidate HCl) is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when...” NCT00799409 ↗ “OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD).” PMID 14595084 ↗ Nov 2003 “Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.” NCT01074294 ↗ “Part I of this study will evaluate the safety and effectiveness of OROS® (methylphenidate HCl) for a period of one year in children with ADHD.” NCT00269815 ↗ “OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days” NCT00880217 ↗ “The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®).” NCT04741516 ↗ “CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.” NCT00901576 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ “CONCERTA (methylphenidate HCl) or placebo” NCT00799487 ↗ Show 9 more sources
Known as	Methylphenidate Hydrochloride	“The purpose of this study is to evaluate the association between blood drug levels and the corresponding scores of commonly used behavioral instruments based upon data...” NCT02536105 ↗ 30 “The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult...” NCT00246233 ↗ “This is a prospective, open-label, within-subject (pre-post), investigator-initiated Phase IV trial evaluating the safety and efficacy of Foquest (multilayer-release...” NCT07710014 ↗ “The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for...” NCT00249353 ↗ “OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017 “A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride (HCl) Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With...” NCT02470234 ↗ “OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗ “Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks. Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks.” NCT02194075 ↗ “The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants).” NCT01879202 ↗ “This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.” NCT01907360 ↗ “pms-METHYLPHENIDATE (methylphenidate hydrochloride) is a racemate consisting of a 1:1 mixture of d-methylphenidate (d-MPH) and l-methylphenidate (l-MPH).” NCT02754258 ↗ Show 20 more sources
Known as	Methylphenidate Hydrochloride (Hcl)	“A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release...” NCT03580005 ↗ 1 “The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill...” NCT01060150 ↗
Known as	methylphenidate hydrochloride- extended release	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	methylphenidate hydrochloride- immediate release	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Methylphenidate Oral Tablet	“Drug: Methylphenidate Oral Tablet” NCT03411434 ↗
Known as	Methylphenidate Transdermal System	“A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ 4 “This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD.” PMID 16481664 ↗ Feb 2006 “methylphenidate transdermal system patch plus placebo capsule” PMID 18312050 ↗ Jan 2008 “Drug: Methylphenidate Transdermal System” NCT00151970 ↗ “Drug: Methylphenidate Transdermal System” NCT00541346 ↗
Known as	Methylphenidate Transdermal System (MTS)	“This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD.” NCT00506285 ↗
Known as	MPD	“repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007 2 “This study was conducted to evaluate the cardiovascular risk of prescribing up to 90 mg of methylphenidate (MPD) daily for treating cocaine dependence.” NCT00015067 ↗ “Methylphenidate (MPD)” NCT00526630 ↗
Known as	MPH	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 65 “Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 “We, the researchers at Hospices Civils de Lyon, designed a randomized, double blind, placebo controlled, crossover trial with a total follow-up duration of 9 weeks to evaluate...” NCT00169611 ↗ “The safety and efficacy of methylphenidate (MPH) in 60 children and adolescents with PDD and behavioral difficulties (such as hyperactivity, impulsiveness and distractibility)...” NCT00025779 ↗ “three modified-release formulations of methylphenidate (MPH) marketed in Canada, two of which meet the criteria for assuming bioequivalence as defined by Health Canada: MPH...” PMID 22512898 ↗ Apr 2012 “This study will evaluate the effectiveness of the stimulant medication methylphenidate (MPH, more commonly known as Ritalin ) when combined (or not combined) with the...” NCT00794040 ↗ “A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy...” NCT02020200 ↗ “The purpose of this study was to investigate the interaction effects between dopamine receptor D4 (DRD4) methylation and prenatal maternal stress on the methylphenidate (MPH)...” PMID 29905488 ↗ Jun 2018 “To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in...” PMID 21488750 ↗ Apr 2011 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “This study aimed to assess the efficacy and tolerability of methylphenidate (MPH) treatment in children and adolescents who met the Diagnostic and Statistical Manual of Mental...” PMID 21586916 ↗ May 2011 Show 55 more sources
Known as	MPH ERCT	“OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017
Known as	MPH-ER	“This treatment trial is aimed at assessing the short-term tolerability and efficacy of liquid-formulation extended-release methylphenidate (MPH-ER) for the treatment of...” PMID 31607204 ↗ Dec 2019
Known as	Mph-IR	“generic immediate-release methylphenidate (MPh-IR) formulation (e.g., Ritalin®)” NCT01377662 ↗ 1 “10 mg methylphenidate immediate release (Mph-IR)” NCT01290276 ↗
Known as	MPH-LA	“methylphenidate modified-release long-acting formulation (MPH-LA) at 40-80 mg/day controlled ADHD symptoms as well as decreased functional impairment with a good tolerability...” PMID 25183661 ↗ Oct 2014
Known as	MPH-MLR	“A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.” PMID 25877989 ↗ Apr 2015
Known as	MTP	“In recent years, studies using methylphenidate (MTP) in the treatment of CRF in solid cancer have been conducted” NCT03218254 ↗
Known as	MTS	“This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD.” PMID 16481664 ↗ Feb 2006 2 “methylphenidate transdermal delivery system (MTS)” PMID 25575616 ↗ Jan 2015 “the methylphenidate transdermal system (MTS)” PMID 20973707 ↗ Oct 2010
Known as	NWP06	“NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.” PMID 23289899 ↗ Jan 2013
Known as	ORADUR-methylphenidate	“ORADUR®-methylphenidate is a new extended-release preparation of methylphenidate.” PMID 36251766 ↗ Oct 2022
Known as	OROS Methylphenidate	“Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of...” NCT01060150 ↗ 20 “OBJECTIVE: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the...” PMID 19440077 ↗ Jun 2009 “To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in...” PMID 21488750 ↗ Apr 2011 “OBJECTIVE: To evaluate the efficacy, safety, and tolerability of adjunctive osmotic-release oral system (OROS) methylphenidate in outpatients with major depressive disorder...” PMID 18312042 ↗ Jan 2008 “OROS-methylphenidate (OROS-MPH) is a once-daily controlled-release formulation of methylphenidate (MPH) developed to overcome some of the limitations associated with IR-MPH and...” PMID 16456216 ↗ Jan 2006 “The drug tested in this trial is OROS methylphenidate. The active ingredient is methylphenidate and the tablet is designed to release the active ingredient gradually to ensure...” NCT00307684 ↗ “OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗ “This community-based study was designed to evaluate treatment outcomes with OROS methylphenidate (MPH) and atomoxetine in children with attentiondeficit/hyperactivity disorder (ADHD)” PMID 16418159 ↗ Sep 2005 “This multicenter, open-label, dose-titration, flexible dose study enrolled adults with ADHD for 6 or 12 months of treatment with OROS methylphenidate.” PMID 21192153 ↗ Feb 2011 “OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD).” PMID 14595084 ↗ Nov 2003 “Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks.” NCT00758160 ↗ Show 10 more sources
Known as	OROS Methylphenidate HCl	“Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of...” NCT01060150 ↗ 3 “The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl (Concerta) can help to control fatigue in patients with breast, gastrointestinal,...” NCT00516269 ↗ “A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder...” NCT00269789 ↗ “OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days” NCT00880217 ↗
Known as	OROS methylphenidate hydrochloride	“Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or...” PMID 22519922 ↗ May 2012 4 “OBJECTIVE: To evaluate the efficacy and safety of individualized dosing within the approved dose range for osmotic-release oral system (OROS) methylphenidate hydrochloride in...” PMID 27487193 ↗ Jan 2017 “OROS methylphenidate hydrochloride (CONCERTA)” NCT00302406 ↗ “CONCERTA (OROS methylphenidate hydrochloride)” NCT00246207 ↗ “OROS methylphenidate hydrochloride” NCT00302393 ↗
Known as	OROS methylphenidate hydrochloride (HCL)	“OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗
Known as	OROS-MPH	“three modified-release formulations of methylphenidate (MPH) marketed in Canada, two of which meet the criteria for assuming bioequivalence as defined by Health Canada: MPH...” PMID 22512898 ↗ Apr 2012 19 “Osmotic release oral system-methylphenidate (OROS-MPH) was evaluated in a 52-wk open-label study in subjects who had previously completed a short-term placebo-controlled trial...” PMID 21798108 ↗ Jul 2011 “This pilot, uncontrolled, open-label study evaluated the safety/tolerability and potential effectiveness of OROS-methylphenidate (OROS-MPH) in adult attention deficit...” PMID 17166338 ↗ Dec 2006 “The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.” NCT00264797 ↗ “a USA study compared different doses of the stimulant drug osmotic-release oral system methylphenidate (OROS-MPH) with a placebo in 33 children” PMID 35844168 ↗ Jul 2022 “A new once-a-day methylphenidate (MPH) formulation, Concerta (methylphenidate HCl) extended-release tablets (OROS MPH), has been developed.” PMID 11581440 ↗ Oct 2001 “or osmotic-release oral system methylphenidate (OROS MPH) (18-54 mg/day based on body weight) arms in a 1:1:1:1:1 ratio” PMID 24840045 ↗ May 2014 “OROS-MPH will be administered orally for 2 months at doses of 18, 36, or 54 milligram (mg) to replace IR-MPH.” NCT00758160 ↗ “Participants will receive OROS-MPH (Concerta® available in Switzerland as first-line treatment for ADHD).” NCT05842330 ↗ “Osmotic-release oral system methylphenidate (OROS-MPH) was included as a reference arm.” PMID 23332456 ↗ Jan 2013 “Concerta (Osmotic Release Oral System Extended Release Methylphenidate HCL, OROS MPH)” NCT01065259 ↗ Show 9 more sources
Known as	Osmotic Release Methylphenidate	“Open-Label Concerta (Osmotic Release Methylphenidate)” NCT01063153 ↗
Known as	Osmotic Release Oral Delivery System (OROS) methylphenidate	“Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks.” NCT00758160 ↗
Known as	osmotic release oral system-methylphenidate	“or osmotic-release oral system methylphenidate (OROS MPH) (18-54 mg/day based on body weight) arms in a 1:1:1:1:1 ratio” PMID 24840045 ↗ May 2014 1 “treated with osmotic release oral system-methylphenidate (OROS-MPH) for 12 wk” PMID 21733227 ↗ Jun 2011
Known as	osmotic-release oral system (OROS) methylphenidate hydrochloride	“Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or...” PMID 22519922 ↗ May 2012
Known as	Osmotic-release oral system methylphenidate (OROS MPH)	“Osmotic-release oral system methylphenidate (OROS MPH)” NCT00889915 ↗
Known as	PR OROS Methylphenidate	“PR OROS Methylphenidate given orally once daily for 5 weeks.” NCT00482313 ↗
Known as	PRC-063	“Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 6 “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021 “long-acting methylphenidate formulation PRC-063” PMID 34637343 ↗ Oct 2021 NCT02139111 ↗ NCT02555150 ↗ NCT02225639 ↗ NCT03618030 ↗
Known as	Quillichew ER	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Quillivant	“Quillivant” NCT03420339 ↗
Known as	Quillivant XR	“Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ 2 “XRMPH in oral suspension supplied as Quillivant XR in 5 mg/ml (Tris Pharma, Monmouth Junction, NJ) will be the active treatment.” NCT05301361 ↗ “Participants in the first Arm will complete a 3-week titration of Methylphenidate HCl (Quillivant XR, 25mg/5mL).” NCT07650643 ↗
Known as	Quillivant XR (liquid)	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Relexxii	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Ritalin	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 39 “The purpose of this study is to determine if methylphenidate (a common brand name is Ritalin), a medicine used for treating older children with Attention Deficit and...” NCT00517504 ↗ “This study will evaluate the effectiveness of the stimulant medication methylphenidate (MPH, more commonly known as Ritalin ) when combined (or not combined) with the...” NCT00794040 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin,...” NCT07306078 ↗ “A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder...” NCT00269789 ↗ “A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder” NCT00269802 ↗ “The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).” NCT00018863 ↗ “Methylphenidate drugs, such as Ritalin or Concerta, have been shown on tests to improve the ability to rapidly absorb information; these tests are called "reaction time tests".” NCT01599975 ↗ “Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD).” NCT00025779 ↗ “The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects” NCT01914822 ↗ Show 29 more sources
Known as	Ritalin (methylphenidate hydrochloride)	“Ritalin (methylphenidate hydrochloride)” NCT01290276 ↗
Known as	Ritalin LA	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	RITALIN LAÒ	“SODOS-MPH (RITALIN LAÒ)” NCT00302354 ↗
Known as	Ritaline LP 10	“Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks” NCT03280251 ↗
Known as	RT2CK17	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03388164 ↗
Known as	SODOS-MPH	“SODOS-MPH (RITALIN LAÒ)” NCT00302354 ↗
Known as	SUB03254MIG	“Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally” NCT05957055 ↗
Known as	t-MPH	“The specific primary aim of this open label study is to determine if use of transdermal Methylphenidate (t-MPH) causes a reduction in fall risk in patients with dementia.” NCT01825577 ↗
Known as	XRMPH	“This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox...” NCT05301361 ↗
Action	Inhibit	“an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007
Modality	Small molecule	“the amphetamine, methylphenidate” PMID 29347996 ↗ Jan 2018
Route	Oral	“Patients receive oral methylphenidate twice daily.” NCT00003266 ↗
Target	ABCB1	“It suggested that methylphenidate was a P-glycoprotein(encoded by MDR1 gene)substrate and showed inhibitory effects on the P-glycoprotein efflux function. Single nucleotide...” NCT00842127 ↗